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INTRODUCTION

FIBROSING CHOLESTATIC HEPATITIS C

Transjugular Liver Biopsy (1/24/14)

 A rare and severe form of recurrent chronic Hepatitis C which
presents within 1 year post-liver transplantation.
 Distinctive characteristics:
- Rapidly progressive with high rates of graft loss and
mortality within the first year of diagnosis.
- Massive HCV RNA levels in the peripheral circulation.

Liver Transplantation:
 Hepatitis C infection is the most common indication for liver
transplantation in the U.S.
 HCV infection of the liver allograft occurs within hours from
circulating virions.
- Serum RNA levels are observed in the first several weeks.
- Acute hepatitis occurs in 2-6 months.
- Chronic hepatitis occurs in 3-9 months.
***Persistence of HCV infection is the rule after
transplantation due to immune suppression.

Risk Factors
Portal tracts with ductular reaction and mild
mixed inflammation; bile duct injury mediated
by lymphocytes; no evidence of endotheliitis

Bridging fibrosis to cirrhosis (stage 3-4 of 4)

Chronic recurrent HCV infection post transplantation

Histology

 There are four distinct patterns of recurrent chronic HCV in the
liver allograft.
- Usual chronic HCV (>70%)
- Fibrosing Cholestatic Hepatitis C (5-10%)
- Plasma cell-rich HCV
- HCV overlapping with rejection or autoimmune hepatitis

CASE PRESENTATION






Canalicular and hepatocellular cholestasis

Pericellular (chicken-wire) fibrosis

 HCV Viral Load (1/20/14): 854,000 IU/mL

 At least ¾ of the characteristic histological features
 Timeframe of >1 month after liver transplantation

Prognosis
 Mean survival time: 8 months before death or re-transplantation

 54 year-old woman with a history of chronic HCV infection
complicated by cirrhosis and hepatocellular carcinoma.
 Liver transplantation (August 2014) from a CMV+, HCV+ donor.
 Post-transplant liver biopsy (11/11/13) showed recurrent HCV
with mild activity (grade 2/4) and periportal fibrosis (stage 2/4).
 On January 19, 2014 presented with worsening malaise, fatigue,
and jaundice.
 Afebrile, lethargic, jaundiced with scleral icterus
 Hepatic Function Tests (1/21/14) :
Albumin:
2.6 mg/dL
(normal 3.5-5)
ALP:
602 U/L
(normal 30-120)
AST:
46 U/L
(normal 0-35)
ALT:
128 U/L
(normal 4-36)
Bilirubin:
15.6 mg/dL
(normal 0.3-1)
Direct bilirubin: 14.1 mg/dL
(normal 0.1-0.3)

Prominent “ductular reaction” resembling biliary obstruction
Cholestasis
Hepatocyte feathery degeneration with lobular disarray
Sinusoidal/pericellular fibrosis

Criteria for Diagnosis

History:

Physical Exam and Labs

 Over-immunosuppression
- High dose cytotoxic therapy, HIV, other solid organ transplant
 High MELD score
 Older donor age

Diagnosis
-

Fibrosing cholestatic hepatitis,
Batts and Ludwig Grade 3 of 4,
stage 3-4 of 4.

Prominent lobular activity with apoptosis,
hepatocyte feathery degeneration

Hospital Course:
Patient was treated with sofosbuvir and ribavirin (1/24/14) however
suffered acute kidney injury. Medications discontinued (2/4/14).
HCV Viral Load (1/27/14) : 2340 IU/mL
Repeat Biopsy (2/24/14)
Persistent canalicular/hepatocellular cholestasis and ductular reaction. No
endotheliitis. Minimal lobular activity. Bridging fibrosis to early cirrhosis (stage
3-4/4).

Treatment
 Successful treatment with conventional HCV therapy is rare.
 Sofosbuvir and simeprevir are FDA-approved only for chronic
HCV infection in native livers but provide an avenue for future
study in transplant patients.
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